Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Selumetinib (plexiform neurofibromas in adults with neurofibromatosis type 1) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A25-147
Last updated

Report documents

  1. Extract of dossier assessment

    Selumetinib (plexiform neurofibromas in adults with neurofibromatosis type 1) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF-Dokument, 237 kB, DE, PDF
    Download file : Extract of dossier assessment (PDF-Dokument, 237 kB, DE, PDF)

  2. Dossier assessment

    Selumetinib (plexiform neurofibromas in adults with neurofibromatosis type 1) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF-Dokument, 714 kB, DE, PDF
    DOI-Link
    https://doi.org/10.60584/A25-147
    Download file : Dossier assessment (PDF-Dokument, 714 kB, DE, PDF)

Drug assessment at a glance

  1. Drug assessment at a glance

    Selumetinib (plexiform neurofibromas in adults with neurofibromatosis type 1) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF-Dokument, 214 kB, EN, PDF
    Download file : Drug assessment at a glance (PDF-Dokument, 214 kB, EN, PDF)

Dossier assessment

Indication:

Treatment of symptomatic, inoperable plexiform neurofibromas in adult patients with neurofibromatosis type 1

Result of dossier assessment:

Added benefit not proven

Additional information

Federal Joint Committee (G-BA)

07-05-2026 A G-BA decision was published.
G-BA documents on this decision

Project details

Project no.
A25-147
Commission
Commission awarded on 17.11.2025 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI
https://doi.org/10.60584/A25-147

Connected Projects

  1. Dossier assessment

    Selumetinib (plexiform neurofibromas in neurofibromatosis type 1, >= 3 to < 18 years) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-146
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Selumetinib (neurofibromatosis) - Assessment according to §35a (para 1., sentence 11) Social Code Book V (expiry of the decision)

    Project no.
    G23-14
    Last updated

    Status: Commission completed

  3. Addendum

    Selumetinib (plexiform neurofibromas in adults with neurofibromatosis type 1) – Addendum to Project A25-147

    Project no.
    A26-33
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page